FFA
PBYI icon

Farther Finance Advisors’s Puma Biotechnology PBYI Stock Holding History

Farther Finance Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$16.8K Buy
1,693
+511
+43% +$4.5K ﹤0.01% 4275
2026
Q2 		$9.6K Buy
1,182
+616
+109% +$4.51K ﹤0.01% 4446
2026
Q1 		$3.83K Buy
566
+37
+7% +$239 ﹤0.01% 4626
2025
Q4 		$3.15K Buy
+529
New +$2.81K ﹤0.01% 4514

Other funds holding PBYI

B
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return

Farther Finance Advisors's PBYI Position: Q3 2026 in Review

Farther Finance Advisors increased its Puma Biotechnology (PBYI) stake by 43% in Q3 2026, buying an estimated $4.5K and bringing the position to 1,693 shares worth $16.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4275.

Farther Finance Advisors first reported a position in PBYI in Q4 2025 and has held it in 4 quarters since. 8 funds tracked by Wall St. Rank hold PBYI as of Q3 2026.

  • Farther Finance Advisors held 1,693 shares of Puma Biotechnology worth $16.8K as of Q3 2026.
  • Farther Finance Advisors bought 511 Puma Biotechnology shares in Q3 2026, an estimated $4.5K.
  • Puma Biotechnology made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #4275 holding.
  • Farther Finance Advisors first reported a position in Puma Biotechnology in Q4 2025 and has held it in 4 quarters since.
  • 8 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.